Full text is available at the source.
Abstract
Adaptive cell therapy (ACT) may enhance personalized cancer treatment for solid tumors by utilizing engineered immune cells.
- ACT has demonstrated significant success in treating blood cancers but faces challenges in solid tumors.
- Challenges include limited immune cell infiltration, varying tumor cell markers, and an environment that suppresses immune responses.
- Strategies to improve ACT's effectiveness focus on engineered T cells, including CAR-T, TCR-T, and tumor-infiltrating lymphocytes (TILs).
- Recent advancements aim to target tumors better, resist signals that suppress immune activity, and prevent tumor cells from evading detection.
- Gene-editing tools like CRISPR/Cas9 are being explored to create next-generation immune cells with improved capabilities and safety.
Simplified